STAT3 and neoplasm: To further investigate whether STAT3 targeting could reverse Olaparib resistance in ovarian cancer cells, we incubated Olaparib-resistant ovarian cancer cells for 48 h with the STAT3 inhibitor Napabucasin, which was shown to impair tumor progression and cisplatin resistance (28).